Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Liver disease

Liver disease

Subtypes of Liver disease

Hepatic impairment 2 Autosomal dominant polycystic liver disease 1 Cholestatic liver injury 1 Genetic metabolic liver diseases 1 Hepatopathy 1 Non-septic acute liver injury 1

32 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Liver disease

50 trials tracked for Liver disease: 13 in phase 3 or 4 and 6 with published results. The most-cited published study has 112 citations.

50Trials tracked
13Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 7 Phase 3 6 Phase 2 10 Phase 1 5 Other / NA 22
  1. Phase 4 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Completed · 112 cited
  2. Phase 4 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Completed · 79 cited
  3. Phase 3 Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG) Completed · 78 cited
  4. Phase 4 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) Completed · 77 cited
  5. Phase 3 Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures Completed · 14 cited
  6. Phase 4 deLIVER: Direct Acting Antiviral Effects on the Liver Completed · 2 cited
Show 44 more trials
  1. Phase 4 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Completed
  2. Phase 4 Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation Completed
  3. Phase 4 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed
  4. Phase 3 BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis Completed
  5. Phase 3 Octreotide in Severe Polycystic Liver Disease Completed
  6. Phase 3 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed
  7. Phase 3 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed
  8. Phase 2 Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis Completed
  9. Phase 2 Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option Completed
  10. Phase 2 Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) Completed
  11. Phase 2 Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection Completed
  12. Phase 2 Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients Completed
  13. Phase 2 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency Completed
  14. Phase 2 Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease Completed
  15. Phase 2 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed
  16. Phase 2 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Completed
  17. Phase 2 Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) Completed
  18. Phase 1 PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers Completed
  19. Phase 1 A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants. Completed
  20. Phase 1 A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease Completed
  21. Phase 1 A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems Completed
  22. Phase 1 Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib Completed
  23. N/A Normal Liver Stiffness by MR Elastography Completed
  24. N/A The SHUNT-V Study for Varices Completed
  25. N/A Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound Completed
  26. N/A Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD) Completed
  27. N/A Sonoelastography: Ultrasound Method to Measure Liver Fibrosis Completed
  28. N/A Breath Analysis Based Disease Biomarkers Completed
  29. N/A Biobehavioral Pathways Underlying Alcohol Use and Health Completed
  30. N/A Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography Completed
  31. N/A The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient Completed
  32. N/A The Patient-Reported Outcomes Project of HCV-TARGET Completed
  33. N/A Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery Completed
  34. N/A Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease) Completed
  35. N/A Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial Completed
  36. N/A GATT-Patch Versus TachoSil in Liver Surgery Completed
  37. N/A Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation Completed
  38. N/A Controlled Attenuation Parameter (CAP) in Liver Allografts Completed
  39. N/A 19 Versus 22-Gauge Needle for EUS-LB Completed
  40. N/A The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. Completed
  41. N/A NASH Fitness Intervention in Thrombosis Trial (NASHFit) Completed
  42. N/A A Study to Evaluate Liver Stiffness With Shear Wave Elastography Completed
  43. N/A A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation Completed
  44. N/A Hepatic Effects of Gastric Bypass Surgery Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Liver disease: what the trials found

New clinical evidence highlights the efficacy of Sofosbuvir/Velpatasvir (SOF/VEL) for liver disease, with a 95.0% sustained virologic response rate at 12 weeks and low rates of serious adverse events (3.5%) or unplanned clinic visits (3.8%) 3. Additionally, Pioglitazone demonstrated statistically significant improvements in NAFLD activity, including steatosis (p=0.005) and lobular inflammation (p=0.02) over 96 weeks 14.

Diagnostic and monitoring tools show varying utility: SHAPE measurement provides a correlation of 0.68 with catheter pressure measurements for diagnosing portal hypertension 4, while HepQuant-SHUNT tests provide specific DSI scores in clinical assessments 10. For surgical and procedural management, Lusutrombopag significantly improved the percentage of patients requiring no platelet transfusion or rescue therapy for bleeding compared to placebo (p<0.0001) 11.

Pharmacological interventions show mixed results: Octreotide was associated with a significant reduction in liver volume (-5.0% vs 0.9%, p=0.048) and a significant decrease in renal volume (p=0.045), though no significant change in GFR was observed 13. Pentoxifylline did not show statistically significant effects on ALT reduction, TNF-alpha levels, or serum leptin levels 12.

Recent results — preliminary, needs further review

  • Efinopegdutide was evaluated in a Phase 2 trial; patients experienced adverse events at rates between 82.1% and 85.7%, with discontinuation due to adverse events ranging from 5.1% to 9.5%. Mean body weight decreased by approximately 3.9% to 7.5% over 28 weeks 1.
  • TachoSil was evaluated for hemostasis; the rate of hemostasis at 3 minutes without rebleeding was 81% in one cohort and 33% in another, with no rebleeding observed between 10 minutes and closure 2.

For the clinician treating this condition

  • Sofosbuvir/Velpatasyr (SOF/VEL) demonstrates high efficacy for sustained virologic response with a manageable safety profile 3.
  • Pioglitazone is effective in improving specific markers of NAFLD, including steatosis and lobular inflammation 14.
  • Lusutrombopag significantly reduces the need for platelet transfusions and rescue therapy for bleeding in patients undergoing procedures 11.
  • Octreotide is associated with a significant reduction in liver volume but does not appear to impact GFR 13.

AI synthesis of 9 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients
Gastroenterology RCT
Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients UDCA Improves Liver Enzymes and Fibrosis in Chronic Liver Disease
This phase IV RCT in 262 patients with chronic liver disease and elevated ALT found that ursodeoxycholic acid 100 mg three times daily for 8…
A phase IV trial found that ursodeoxycholic acid (UDCA) significantly reduced ALT levels and improved fibrosis scores in patients with chron…
May 19, 2026
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
Allergy & Immunology Sys. Review
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
Frontiers May 18, 2026
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Oncology Sys. Review
Narrative review explores macrophage reprogramming for liver fibrosis and MASH Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Frontiers May 17, 2026
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment
Drug Pipeline Sys. Review
Systematic review uses PBPK modeling to guide niraparib dose adjustments in hepatic impairment New Dose Rules for Niraparib in Liver Disease Protect Patients
This systematic review uses physiologically based pharmacokinetic (PBPK) modeling to predict optimal niraparib dosing in patients with hepat…
A smart computer model now shows how to safely lower niraparib doses for cancer patients with liver disease, protecting them from harmful si…
Frontiers May 11, 2026
Narrative review explores aryl hydrocarbon receptor's dual role in liver injury and protection
Orthopedics & Sports Medicine Sys. Review
Narrative review explores aryl hydrocarbon receptor's dual role in liver injury and protection Liver's Secret Switch Flips Between Harm and Healing
This narrative review examines the aryl hydrocarbon receptor (AhR) in liver disease. AhR activation drives liver damage through mitochondria…
Your liver has a hidden sensor that pollution can flip to destroy mode but scientists just found how to lock it in repair mode
Frontiers May 9, 2026
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications
Diabetes & Endocrinology Sys. Review
Narrative review discusses Ganoderma lucidum polysaccharides for diabetes and related complications New research shows mushroom compounds may help control blood sugar and fix organ damage
This narrative review examines the theoretical potential of Ganoderma lucidum polysaccharides (GLPs) for diabetes and associated conditions.
A common mushroom extract could help lower blood sugar and heal organ damage for millions of people with diabetes
Frontiers May 1, 2026
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency
Gastroenterology Meta-analysis
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency 1 in 4 children with A1AT deficiency develop cirrhosis
This systematic review and meta-analysis examined children with confirmed Pi*ZZ alpha-1 antitrypsin deficiency to assess liver outcomes.
New analysis finds 41% of children with A1AT deficiency have liver fibrosis and 17% have cirrhosis.
May 1, 2026
Single 6 mg erdafitinib dose shows similar pharmacokinetics in mild or moderate hepatic impairment versus healthy controls
Gastroenterology Phase I
Single 6 mg erdafitinib dose shows similar pharmacokinetics in mild or moderate hepatic impairment versus healthy controls Single dose of erdafitinib showed no dose changes needed for mild or moderate liver issues
This Phase 1 open-label single-dose study evaluated pharmacokinetics of erdafitinib in 26 participants with hepatic impairment versus health…
A single dose of erdafitinib worked well in people with mild or moderate liver problems, showing no need for dose adjustments.
May 1, 2026
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions
Drug Pipeline Meta-analysis
Systematic review synthesizes Rhaponticum species chemistry, traditional uses, and research gaps across multiple conditions Ancient Herbs May Help Modern Health
This systematic review synthesizes data on Rhaponticum species, covering 24 documented species worldwide and their applications for conditio…
Imagine walking through a garden filled with wildflowers.
Frontiers Apr 24, 2026
Narrative review of bile-based traditional Chinese medicines for liver diseases
Drug Pipeline Sys. Review
Narrative review of bile-based traditional Chinese medicines for liver diseases Bile-Based Medicine May Heal Your Liver, But It Can Also Hurt It
This narrative review examines bile-based traditional Chinese medicines used in the management of liver diseases.
Traditional medicines made from animal bile can help treat liver disease, but they contain a complex mix of helpful and potentially harmful …
Frontiers Apr 24, 2026
Preclinical deep learning framework shows improved dose prediction for unseen cancer sites
Radiology & Imaging
Preclinical deep learning framework shows improved dose prediction for unseen cancer sites A Heavy Burden on Doctors
This is a preclinical development study of a deep learning framework for radiotherapy dose prediction.
A new AI tool can plan radiation doses for many different cancers at once.
medRxiv Apr 24, 2026
Preclinical analysis of gnomAD and ClinVar databases on ADPLD variant frequencies
Nephrology
Preclinical analysis of gnomAD and ClinVar databases on ADPLD variant frequencies Genetic variants linked to polycystic liver disease found in many people
This other publication is a preclinical analysis of gnomAD and ClinVar databases for predicted pathogenic variants in ADPLD genes.
Analysis of large genetic databases shows predicted pathogenic variants for polycystic liver disease occur in about 1 in 95 people, with hig…
medRxiv Apr 23, 2026

Questions about Liver disease

Does mitochondrial dysfunction play a role in liver injury?

Yes, mitochondrial dysfunction is a key driver of liver injury, contributing to cell death and disease progression in conditions like fatty liver and alcohol-associated liver disease.

Full answer →
Does activating the aryl hydrocarbon receptor cause liver damage?

Activating the aryl hydrocarbon receptor can cause liver damage or protect it depending on the specific signals and context, acting as a double-edged sword in liver health.

Full answer →